Loading...
•
Mar 31, 2025
STERIS Q4 2025 Earnings Report
STERIS reported modest growth in Q4 2025 driven by strong performance in Healthcare and Applied Sterilization Technologies segments.
Key Takeaways
STERIS delivered a 4% revenue increase in Q4 2025, supported by solid gains in service and consumables, though Life Sciences saw a decline due to divestiture impacts.
Q4 revenue rose to $1.5 billion, up 4% year-over-year.
Adjusted EPS increased to $2.74 from $2.41 a year ago.
Healthcare segment showed strong service and consumables growth.
Life Sciences revenue declined due to business divestiture and reduced capital equipment sales.
Revenue by Segment
Forward Guidance
STERIS expects 6-7% revenue growth and up to 10% increase in adjusted EPS in FY26.
Positive Outlook
- Expected 6–7% revenue growth in FY26.
- Currency impact anticipated to be neutral.
- Adjusted EPS forecasted between $9.90 and $10.15.
- Free cash flow expected around $770 million.
- Capital expenditures planned at $375 million.
Challenges Ahead
- Tariffs expected to reduce pre-tax profit by $30 million.
- Labor and energy cost pressures persist.
- Impact of CECS divestiture on Life Sciences segment.
- Capital equipment revenue remains volatile.
- Potential headwinds from inflation and global market conditions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...